SalioGen Therapeutics: Funding, Investors & Team (Sep 2026)
SalioGen Therapeutics is a gene coding company that develops potentially curative therapies for patients with inherited disorders. Its Gene Coding approach is guided by our Exact DNA Integration Technology (EDIT) platform, a genome engineering technology that leverages proprietary mammal-derived enzymes they call Saliogase. With broad applicability, non-viral delivery capabilities of any size gene, and significant manufacturing advantages, EDIT has the potential to transform the treatment paradigm for inherited disorders and beyond.
SalioGen Therapeutics has raised $115M across 1 funding round on record, the most recent a Series B of $115M announced in Jan 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
SalioGen Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2022.
SalioGen Therapeutics Funding Rounds
SalioGen Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
SalioGen Therapeutics Funding Compared to Other Biotechnology Startups
SalioGen Therapeutics' latest round of $115M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like SalioGen Therapeutics in Biotechnology and Burlington
Companies Similar to SalioGen Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
SalioGen Therapeutics Funding FAQs
What does SalioGen Therapeutics do?
SalioGen Therapeutics is a gene coding company that develops potentially curative therapies for patients with inherited disorders. Its Gene Coding approach is guided by our Exact DNA Integration Technology (EDIT) platform, a genome engineering technology that leverages proprietary mammal-derived enzymes they call Saliogase. With broad applicability, non-viral delivery capabilities of any size gene, and significant manufacturing advantages, EDIT has the potential to transform the treatment paradigm for inherited disorders and beyond.
How much funding has SalioGen Therapeutics raised?
SalioGen Therapeutics has raised $115M across 1 round on record. The most recent is a Series B of $115M announced in Jan 2022.
When did SalioGen Therapeutics last raise funding?
SalioGen Therapeutics' most recent funding round on record is a Series B of $115M, announced in Jan 2022.
Who is the CEO of SalioGen Therapeutics?
Ray Tabibiazar is listed as CEO at SalioGen Therapeutics.
Where is SalioGen Therapeutics headquartered?
SalioGen Therapeutics is based in Burlington, Massachusetts, United States.
How many employees does SalioGen Therapeutics have?
SalioGen Therapeutics is in the 11-50 employee band.
How does SalioGen Therapeutics' funding compare to other Biotechnology startups?
SalioGen Therapeutics' latest round of $115M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's SalioGen Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for SalioGen Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.